S-531011: Clinical Trials

3 trials of S-531011, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 not yet recruiting, 1 recruiting, 1 withdrawn. 3 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Not yet recruiting 1, Recruiting 1, Withdrawn 1
Phase 12Not yet recruiting 1, Recruiting 1

Follow S-531011: new trials by email Literature Review of S-531011 trials Research Report on S-531011

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer
S-531011, HD-XRT - Phase II, S-531011
Phase 2WithdrawnM.D. Anderson Cancer Center2026-08-122026-09-11
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
S-531011, Fruquintinib, Pembrolizumab - Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer
Phase 1 / Phase 2Not yet recruitingNational Cancer Center Hospital East682026-05-012026-05-18
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
S-531011, Pembrolizumab, Bevacizumab - Solid Tumors
Phase 1 / Phase 2RecruitingShionogi2822022-05-302026-03-18

Conditions studied

Colorectal Neoplasms (2)

Sponsors

M.D. Anderson Cancer Center (1)  ·  National Cancer Center Hospital East (1)  ·  Shionogi (1)

Countries

Japan (1)  ·  United States (1)

Top investigators

Daniel Haldar, MD (1)